Akynzeo® (fosnetupitant and palonosetron) injection

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Akynzeo (fosnetupitant and palonosetron) for injection is a combination of palonosetron, a serotonin-3 (5-HT₃) receptor antagonist and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist. Palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Akynzeo for injection is indicated in combination with dexamethasone for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy in adults.

<table>
<thead>
<tr>
<th>Highly Emetogenic Chemotherapy (HEC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carboplatin</td>
</tr>
<tr>
<td>Dacarbazine</td>
</tr>
<tr>
<td>Mechlorethamine</td>
</tr>
</tbody>
</table>

The following chemotherapy can be considered HEC in certain patients:

| Dactinomycin | Irinotecan | Oxaliplatin | Trabectedin |
| Daunorubicin | Methotrexate ≥ 250 mg/m² |

The following regimen can be considered HEC:

FOLFOX
Dosing

Max units (per dose and over time):
- 1 vial (fosnetupitant 235 mg and palonosetron 0.25mg) on day 1 of chemotherapy per 7 days

Guideline

Akynzeo (fosnetupitant and palonosetron) is considered when the following criteria are met:
- Patient is 18 years of age or older; **AND**
- Akynzeo will be used in combination with dexamethasone; **AND**
- Patient is undergoing highly emetogenic cancer chemotherapy (HEC); **AND**
- Patient has failed a trial a 5-HT3 receptor antagonist (e.g., ondansetron, granisetron, palonosetron) in combination with a NK1 receptor antagonist (e.g. aprepitant, fosaprepitant, rolapitant) while receiving the current chemotherapy regimen, as defined as:
  - Two or more episodes of vomiting attributed to the current chemotherapy regimen; **OR**
  - Clinically significant adverse effects attributed to the 5-HT3 or NK1 receptor antagonist; **OR**
  - Contraindications to alternative 5-HT3 or NK1 receptor antagonist

Coverage for Akynzeo (fosnetupitant and palonosetron) may be renewed when the following criteria are met:
- Patient continues to meet the criteria identified in the initial approval criteria above; **AND**
- Disease response; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, serotonin syndrome, etc.

Limitations/Exclusions

- Approval will be granted for 6 months and may be renewed
- Akynzeo use for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy will be considered investigational and not be covered

Applicable Procedure Codes

Revisions
12/3/2018 – Added J1454 and removed J3590, C9033 from Applicable Procedure Codes.

| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg |

Applicable Diagnosis Codes

| R11.0  | Nausea                      |
| R11.10 | Vomiting, unspecified      |
| R11.11 | Vomiting without nausea   |
R11.12  Projectile vomiting
R11.13  Vomiting of fecal matter
R11.14  Bilious vomiting
R11.2   Nausea with vomiting, unspecified
T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5D Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T45.1X5S Adverse effect of antineoplastic and immunosuppressive drugs, sequela
Z51.11  Encounter for antineoplastic chemotherapy
Z51.12  Encounter for antineoplastic immunotherapy

References